A previous study showed that O-linked β-N-acetylglucosamine modification of MR enhanced its protein expression and transcriptional activity in vitro and in vivo under high-glucose conditions [7], suggesting a potential advantage of MR antagonists in patients with resistant hypertension and diabetic nephropathy. This evidence concerns the gene NR3C2 and Hypertension resistant to conventional therapy.